In this issue of *Medical Principles and Practice*, Celik et al. \[[@B1]\] reported an independent negative correlation between serum uric acid (SUA) levels and blood flow velocity of the left atrial appendage (LAA) in 153 patients with atrial fibrillation (AF). Multivariate regression analysis showed that male gender (p ≤ 0.001), age (p = 0.009) and SUA levels (p = 0.010) were independent predictors of the LAA peak flow velocity \[[@B1]\]. The clinical implication of a low LAA flow velocity was based on its association with an increased risk of thromboembolism. Therefore, elevated SUA concentrations may also be linked to an increased thromboembolic risk, as shown in a recent study \[[@B2]\].

Celik et al. \[[@B1]\] mentioned the relationship between increased SUA levels and AF, a finding that was supported by a recent meta-analysis \[[@B3]\]. Furthermore, hyperuricaemia had been shown to predict stroke incidence in AF patients \[[@B4]\]. Elevated SUA levels have also been associated with increased cardiovascular (CV) morbidity and mortality, as Celik et al. \[[@B1]\] stated. Patients with carotid atherosclerosis and peripheral artery disease may also have increased SUA concentrations compared with controls \[[@B5]\]. Furthermore, several CV risk factors including dyslipidaemia, diabetes, obesity, hypertension, metabolic syndrome, non-alcoholic fatty liver disease and kidney dysfunction have been related to hyperuricaemia \[[@B5],[@B6]\]. In diabetic patients, elevated SUA levels were linked to both micro- and macrovascular complications \[[@B7]\]. These associations confound the relationship of SUA with CV risk, making it difficult to isolate the contribution of SUA. Large numbers of individuals are needed to help compensate for this limitation, using multivariate analyses or selecting very specific patient groups (e.g. by gender, age and obesity) to decrease heterogeneity.

A key question is whether lowering of SUA decreases the risk of CV. In this context, allopurinol and febuxostat (both inhibitors of xanthine oxidase) have been reported to improve CV outcomes \[[@B8]\], although the data are limited and further research is needed. Several drugs that may reduce CV risk were also shown to decrease SUA levels (e.g. captopril, enalapril, ramipril, losartan and amlodipine, metformin, pioglitazone, atorvastatin, simvastatin, ezetimibe and fenofibrate) \[[@B5],[@B7]\]. These effects may not be widely known, and their contribution to additional risk reduction is not clear, as the data are limited. More importantly, in the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial \[[@B9]\] and the Greek Atorvastatin and Coronary-Heart Disease Evaluation (GREACE) study \[[@B10]\], the drug-induced SUA-lowering effect was reported to contribute to CV risk reduction. In the LIFE trial \[[@B9]\], elevated SUA concentrations significantly correlated with an increased risk of CV events \[hazard ratio (HR) 1.024, 95s% confidence interval (CI) 1.017--1.032 for every 10 μmol/l, p \< 0.0001\] in the entire study population. With regard to gender differences, this association was significant only in women (HR 1.025, 95s% CI 1.013--1.037, p \< 0.0001). In the GREACE study \[[@B10]\], the HR for coronary heart disease-related events was 0.89 (95s% CI 0.78--0.96, p = 0.03) for every 0.5-mg (30 μmol/l) reduction in SUA levels and 0.76 (95s% CI 0.62--0.89, p = 0.001) for every 1-mg (60 μmol/l) reduction. In contrast, the HR was 1.14 (95s% CI 1.03--1.27, p = 0.02) with every 0.5-mg increase in SUA levels and 1.29 (95s% CI 1.17--1.43, p = 0.001) with every 1-mg increase \[[@B10]\].

In conclusion, hyperuricaemia seems to be independently associated with CV diseases, resulting in increased morbidity and mortality. SUA-lowering drugs may ameliorate CV risk, and certain drugs used to prevent CV disease may decrease SUA levels as an added action. Further large prospective studies are needed to establish the role of SUA in daily clinical practice.
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